WOOJUNG BIO, Inc. Logo

WOOJUNG BIO, Inc.

Offers pre-clinical CRO services, research facility engineering, and startup incubation.

215380 | KO

Overview

Corporate Details

ISIN(s):
KR7215380007
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄기흥로 593-8 (영천동, 우정바이오 신약클러스터I), 화성시

Description

WOOJUNG BIO, Inc. is a bio-infrastructure company providing an integrated platform for research and development in the life sciences. The company's core activities are structured around three main pillars. First, it offers comprehensive pre-clinical Contract Research Organization (CRO) services, including efficacy studies, safety evaluations, and pharmaceutical analysis, utilizing its advanced animal laboratory facilities. Second, it specializes in the engineering and construction of modernized research environments, offering complete solutions for building and managing smart laboratories, animal rooms, and GMP-compliant clean rooms. Third, through its 'WOOJUNG BIO Cluster' open innovation platform, it provides R&D infrastructure, incubation, and acceleration support for bio-ventures and startups, aiming to foster the new drug development ecosystem and help transform innovative ideas into therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-04-20 00:00
[기재정정]신규시설투자등
Korean 13.5 KB
2021-04-14 00:00
단일판매ㆍ공급계약체결
Korean 9.9 KB
2021-04-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 40.1 KB
2021-04-01 00:00
주식등의대량보유상황보고서(일반)
Korean 124.3 KB
2021-03-30 00:00
[기재정정]사업보고서 (2020.12)
Korean 1.2 MB
2021-03-29 00:00
정기주주총회결과
Korean 25.5 KB
2021-03-19 00:00
감사보고서제출
Korean 17.4 KB
2021-03-19 00:00
사업보고서 (2020.12)
Korean 527.2 KB
2021-03-15 00:00
기타경영사항(자율공시)(전환가액 조정(전환우선주))
Korean 10.7 KB
2021-03-12 00:00
주주총회소집공고
Korean 134.7 KB
2021-03-12 00:00
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 17.8 KB
2021-03-12 00:00
주주총회소집결의
Korean 15.0 KB
2021-03-03 00:00
주식등의대량보유상황보고서(일반)
Korean 105.7 KB
2021-02-25 00:00
[기재정정]신규시설투자등
Korean 18.6 KB
2021-02-25 00:00
[기재정정]신규시설투자등
Korean 12.7 KB

Automate Your Workflow. Get a real-time feed of all WOOJUNG BIO, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WOOJUNG BIO, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WOOJUNG BIO, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.